Loading clinical trials...
Loading clinical trials...
An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML
Conditions
Interventions
NEX-18a injection
Azacitidine Injection
Locations
2
Sweden
Karolinska University Hospital Huddinge
Huddinge, Sweden
Kliniska Forsknings och Utvecklings Enheten KFUE
Uppsala, Sweden
Start Date
April 27, 2021
Primary Completion Date
February 10, 2022
Completion Date
February 10, 2022
Last Updated
October 17, 2023
NCT06465953
NCT05768932
NCT06859424
NCT06994676
NCT07451912
NCT06660368
Lead Sponsor
Nanexa AB
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions